Lobelia

Lobeline binds alpha4beta2 and alpha3beta2 neuronal nicotinic acetylcholine receptors with high affinity (Ki 4-30 nM) and acts as a partial agonist/antagonist. Combined with nicotine replacement or varenicline, effects are unpredictable: additive nicotinic toxicity (nausea, hypertension, tachycardia) or antagonism of smoking-cessation drug efficacy.

Avoid concurrent use with nicotine patches, gum, or varenicline. If used for smoking cessation, pick one pharmacologic agent. Counsel patients that lobelia has a narrow therapeutic window; the FDA withdrew OTC lobeline smoking-cessation products in 1993.

Documented case reports indicate that lobelia increases serum lithium concentrations, likely through its natriuretic/diuretic effects altering renal lithium clearance. This can precipitate lithium toxicity (tremor, confusion, nephrotoxicity).

Contraindicated in patients on lithium. If exposure occurs, monitor serum lithium level and renal function within 3-5 days and observe for toxicity signs.

Lobeline has biphasic cardiovascular effects: low doses produce nicotine-like tachycardia and hypertension through carotid chemoreceptor stimulation, while higher doses cause bradycardia and hypotension. Unpredictable additive or antagonistic effects can destabilize blood pressure control.

Avoid concurrent use. If co-administered, monitor BP and heart rate frequently. Discontinue lobelia if BP becomes unstable.

Although lobeline is primarily a respiratory stimulant, overdose produces respiratory depression, CNS depression, and coma. Pharmacodynamic overlap with other CNS depressants may precipitate severe sedation or respiratory failure at toxic doses.

Avoid combination. Warn patients of the narrow therapeutic-to-toxic margin (toxicity documented at 8 mg of pure lobeline or 50 mg dried herb).

Lobeline inhibits the vesicular monoamine transporter-2 (VMAT2) and dopamine re-uptake, altering presynaptic dopamine handling. Theoretical antagonism of antipsychotic efficacy or additive extrapyramidal risk is plausible.

Avoid concurrent use until more data are available. Monitor for loss of antipsychotic effect or emergence of movement disorders.

Lobeline stimulates catecholamine release from autonomic ganglia and adrenal medulla (via nicotinic agonism). Combined with MAOIs, accumulated norepinephrine and dopamine could precipitate hypertensive crisis.

Contraindicated in patients on MAOIs. Separate from MAOI discontinuation by at least 14 days.

Lobeline is a P-glycoprotein inhibitor in vitro and has been proposed to reverse multidrug resistance in tumor cells. In patients, this could increase systemic exposure and toxicity of P-gp substrate chemotherapeutics.

Avoid use during active chemotherapy without oncologist approval. Monitor for cytotoxic drug toxicity (myelosuppression, neuropathy) if exposure occurs.